Current oncology最新文献_第5页

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. 在标准剂量或低剂量伊匹单抗治疗晚期黑色素瘤进展后，高剂量伊匹单抗加替莫唑胺的显著反应

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-28 DOI: 10.3390/curroncol32030144

Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson-Wayman, Debra Jamison, Dan Sageser, Joanne Jeter, Tawnya L Bowles, Donald M Cannon, Ben Haaland, Joyce D Schroeder, David A Nix, Aaron Atkinson, John Hyngstrom, Jordan McPherson, Aik-Choon Tan, Siwen Hu-Lieskovan

{"title":"Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma.","authors":"Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson-Wayman, Debra Jamison, Dan Sageser, Joanne Jeter, Tawnya L Bowles, Donald M Cannon, Ben Haaland, Joyce D Schroeder, David A Nix, Aaron Atkinson, John Hyngstrom, Jordan McPherson, Aik-Choon Tan, Siwen Hu-Lieskovan","doi":"10.3390/curroncol32030144","DOIUrl":"10.3390/curroncol32030144","url":null,"abstract":"Patients with advanced melanoma who progress on standard-dose ipilimumab (Ipi) + nivolumab continue to have poor prognosis. Studies support a dose-response activity of Ipi, and one promising combination is Ipi 10 mg/kg (Ipi10) + temozolomide (TMZ). We performed a retrospective cohort analysis of patients with advanced melanoma treated with Ipi10 + TMZ in the immunotherapy refractory/resistant setting (n = 6, all progressed after prior Ipi + nivolumab), using similar patients treated with Ipi3 + TMZ (n = 6) as comparison. Molecular profiling by whole-exome sequencing (WES) and RNA-sequencing (RNA-seq) of tumors harvested through one responder's treatment was performed. With a median follow up of 119 days, patients treated with Ipi10 + TMZ had a statistically significant longer median progression-free survival of 144.5 days (range 27-219) vs. 44 (26-75) in Ipi 3 mg/kg (Ipi3) + TMZ, p = 0.04, and a trend of longer median overall survival of 154.5 days (27-537) vs. 89.5 (26-548). Two patients in the Ipi10 + TMZ cohort had a partial response, and both responders had BRAF V600E mutant melanoma. RNA-seq showed enrichment of inflammatory signatures, including interferon responses in metastases after Ipi10 + TMZ compared to the primary tumor, and downregulated negative immune regulators. Ipi10 + TMZ demonstrated efficacy, including dramatic responses in patients refractory to prior Ipi + anti-PD1. Molecular data suggest a potential threshold of Ipi dose for activation of sufficient anti-tumor immune response, and higher doses are required for some patients.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada. 双特异性抗体在加拿大治疗弥漫性大b细胞淋巴瘤的最佳应用

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-28 DOI: 10.3390/curroncol32030142

Isabelle Fleury, David MacDonald, Mona Shafey, Anna Christofides, Laurie H Sehn

引用次数: 0

Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells. 乳腺癌和肿瘤微环境：免疫细胞的关键作用。

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-28 DOI: 10.3390/curroncol32030143

Tânia Moura, Paula Laranjeira, Olga Caramelo, Ana M Gil, Artur Paiva

引用次数: 0

Downregulation of the Unfolded Protein Response Links Metformin Treatment to Good Clinical Outcomes in Colorectal Cancer Patients. 未折叠蛋白反应的下调将二甲双胍治疗与结直肠癌患者的良好临床结果联系起来。

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-27 DOI: 10.3390/curroncol32030138

Mary L Fay, Chris Nicol, Christine Orr, Brooke Wilson, David Hurlbut, Harriet Feilotter, Scott Davey

{"title":"Downregulation of the Unfolded Protein Response Links Metformin Treatment to Good Clinical Outcomes in Colorectal Cancer Patients.","authors":"Mary L Fay, Chris Nicol, Christine Orr, Brooke Wilson, David Hurlbut, Harriet Feilotter, Scott Davey","doi":"10.3390/curroncol32030138","DOIUrl":"10.3390/curroncol32030138","url":null,"abstract":"Type 2 diabetes is a risk factor for colorectal cancer (CRC) development and progression. However, metformin-treated diabetic CRC patients tend to have better clinical outcomes than those managed by other means. To better characterize the molecular underpinnings of metformin's protective effects, we performed a targeted transcriptomic analysis of primary CRC tissue samples (n = 272). A supervised learning algorithm pinpointed molecular features that discriminate between metformin-treated and diet-controlled diabetic CRC samples, as well as those that discriminated between non-diabetic samples based on their five-year overall survival status. Our results show downregulation of TMEM132 in metformin-treated samples (p = 0.05) and non-diabetics with good clinical outcomes (p = 0.05) relative to diet-controlled and non-diabetics with poor survival, respectively. Furthermore, upregulation of SCNN1A is observed in metformin-treated samples (p = 0.04) and non-diabetics with good clinical outcomes (p = 0.01) relative to diet-controlled samples and those with poor clinical outcomes, respectively. We also show that the antiapoptotic protein sFas is downregulated in metformin-treated samples relative to diet-controlled samples (p = 0.005). These findings suggest a role for the unfolded protein response in mediating metformin-related CRC-protective effects by enhancing apoptosis and suggest the investigation of these proteins as targets for novel CRC therapies.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cryotherapy in the Treatment of Extra-Abdominal Desmoid Tumors-A Review. 冷冻治疗腹外硬纤维瘤的研究进展。

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-27 DOI: 10.3390/curroncol32030137

Kadhim Taqi, Cecily Stockley, Melissa Wood, Stefan Przybojewski, Antoine Bouchard-Fortier, Lloyd Mack

引用次数: 0

Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada. 加拿大对转移性癌症患者进行及时、公平的先进生物标志物检测。

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-27 DOI: 10.3390/curroncol32030141

Brandon S Sheffield, Shantanu Banerji, Allen Chankowsky, Shaan Dudani, Sharlene Gill, Zuzanna Gorski, Shaqil Kassam, Cassandra Macaulay, Mita Manna, Kirstin Perdrizet, Ravi Ramjeesingh, Monika Slovinec D'Angelo, Filomena Servidio-Italiano

{"title":"Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada.","authors":"Brandon S Sheffield, Shantanu Banerji, Allen Chankowsky, Shaan Dudani, Sharlene Gill, Zuzanna Gorski, Shaqil Kassam, Cassandra Macaulay, Mita Manna, Kirstin Perdrizet, Ravi Ramjeesingh, Monika Slovinec D'Angelo, Filomena Servidio-Italiano","doi":"10.3390/curroncol32030141","DOIUrl":"10.3390/curroncol32030141","url":null,"abstract":"The explosion in biomarker testing over the past two decades continues to transform cancer care in Canada and around the world. Precision medicine is supported by identifying actionable mutations that direct therapeutic choices, thus improving survival and quality of life, especially for patients with advanced/metastatic disease. In addition, our growing understanding of the genetic basis of cancer is advanced by research employing ever-expanding databases of genetic mutations, therapies and outcomes. Despite this promising progress, however, access to biomarker testing remains inequitable across Canada, to the detriment of patients. Several underlying factors contribute to this situation, including the need for investment in and standardization of laboratory medicine infrastructure and processes, and the lack of suitable methods for cost/benefit evaluations to inform funding decisions. In 2024, a Canadian conference brought together patients, clinicians, researchers, policy-makers and scientists to address \"Equitable Access to Advanced Biomarker Testing for Canadian Metastatic Cancer Patients\". Two major themes arose from the conference: the urgent need to adopt comprehensive genomic profiling (CGP) as a standard of care across Canada, and the emerging role of liquid biopsy in accelerating access to biomarker testing for patients with advanced/metastatic cancer.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Putting Patients First: Pragmatic Trials in Gynecologic Oncology. 以病人为先：妇科肿瘤学的实用试验。

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-27 DOI: 10.3390/curroncol32030139

Laura Hopkins, Mark Clemons, Karen Bemister, Chris Booth, Shannon Kadar, Paul Karanicolas, Julie Mulligan, Marie-France Savard, Ian Tannock, Alicia Tone, Helen MacKay

{"title":"Putting Patients First: Pragmatic Trials in Gynecologic Oncology.","authors":"Laura Hopkins, Mark Clemons, Karen Bemister, Chris Booth, Shannon Kadar, Paul Karanicolas, Julie Mulligan, Marie-France Savard, Ian Tannock, Alicia Tone, Helen MacKay","doi":"10.3390/curroncol32030139","DOIUrl":"10.3390/curroncol32030139","url":null,"abstract":"In November 2024, the Society of Gynecologic Oncology of Canada hosted a 2-day, interdisciplinary Pragmatic Clinical Trials (PCTs) Workshop with the goal of launching an initiative to develop and promote PCTs within the Canadian gynecologic oncology research environment. The programme brought together multiple stakeholders, including patients with ovarian cancer, patient advocates, experts in PCTs, gynecologic oncologists, medical oncologists and clinical fellows. Foundational elements of pragmatism were emphasized in the context of the primary goal of PCTs, showing the real-world effectiveness of interventions in broad patient groups. Examples of how PCT outcomes can inform and influence clinical decision making and health policy were presented in the context of those outcomes that matter most to patients with cancer. The patients and patient advocates had the essential role of helping clinical investigators co-design PCT protocols to answer common, important, and practical questions that focus on outcomes that matter to patients. These endpoints included overall survival, quality of life and promotion of informed patient decision making. Tangible workshop outcomes included the development of several new proposals for PCTs inspirited and directed by the patient voice. Further educational initiatives to engage clinical gynecologic oncology investigators at all stages in their career are being planned.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events. 通过管理免疫相关不良事件的虚拟加拿大实践社区加强护理。

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-27 DOI: 10.3390/curroncol32030140

Khashayar Esfahani, John Walker, Kevin Bambury, Eoin O'Carroll, Stephanie Snow

{"title":"Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events.","authors":"Khashayar Esfahani, John Walker, Kevin Bambury, Eoin O'Carroll, Stephanie Snow","doi":"10.3390/curroncol32030140","DOIUrl":"10.3390/curroncol32030140","url":null,"abstract":"The advent of immune checkpoint inhibitors (ICIs) has significantly transformed cancer treatment outcomes. However, these therapies can induce immune-related adverse events (irAEs) that may affect any organ system, sometimes requiring specialized expertise. As ICIs are increasingly used across various tumor types and in earlier treatment settings, not all practitioners have the necessary support network to handle complex irAEs. To address this gap, we collaborated with ONCOassist, a leading app for oncology professionals, to establish the first virtual Canadian Community of Practice (CoP) focused on irAEs. The CoP facilitates continuous learning and improves patient care among Canadian clinicians treating patients with immunotherapy by providing a platform for knowledge exchange and peer-to-peer support. This article outlines the development and growth of the CoP on irAEs, highlighting both successes and challenges. As of May 2024, over a year since its inception, the CoP on irAEs has attracted almost 130 Canadian oncology healthcare professionals, and peer-to-peer interactions and engagement continue to increase. To ensure its long-term sustainability, we plan to evolve and adapt the CoP to meet the needs of the oncology community and address clinical challenges associated with new therapies.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of Vitamin D and Its Analogues in Type-B Lymphomas. 维生素D及其类似物对b型淋巴瘤的影响。

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-26 DOI: 10.3390/curroncol32030135

Valerio Basile, Alessandro Allegra, Herbert Ryan Marini, Massimiliano Berretta, Barbara Granata, José Freni, Domenico Puzzolo, Fabio Stagno, Paola Midiri, Valentina Urzì Brancati, Letteria Minutoli

{"title":"Influence of Vitamin D and Its Analogues in Type-B Lymphomas.","authors":"Valerio Basile, Alessandro Allegra, Herbert Ryan Marini, Massimiliano Berretta, Barbara Granata, José Freni, Domenico Puzzolo, Fabio Stagno, Paola Midiri, Valentina Urzì Brancati, Letteria Minutoli","doi":"10.3390/curroncol32030135","DOIUrl":"10.3390/curroncol32030135","url":null,"abstract":"Lymphomas represent a heterogeneous group of blood tumors, generally divided into non-Hodgkin lymphoma (NHL) (90% of all lymphomas) and Hodgkin lymphoma (HL). High-grade NHL can rapidly progress so that new strategies and potentially therapeutical options are needed. Recently, it was shown that Vitamin D (VitD) inhibits the growth of cancer cells, controls their invasion and metastasis, and strengthens the antitumor activity of various types of chemotherapeutic anticancer agents. Therefore, we reviewed the recent literature about the influence of VitD and its analogues (VDAs) on the treatment and the prognosis of B-cell lymphomas. As to the in vitro studies in different cell lines, VitD3 and VDAs enhanced the anti-proliferative efficacy of various chemotherapeutics and increased the expression of VitD receptor. In in vivo studies, blood levels of VitD were considered: higher values of plasma bioavailable VitD were correlated with better progression-free survival (PFS) and overall survival (OS), while an unfavorable PFS and OS were observed in VitD deficient groups. No clinical trial was made on the analogs, thus confirming the absence of in vivo positive role of these synthetic drugs. In conclusion, higher levels of circulating VitD are related to improved OS, reduced cancer-specific mortality, and better disease-free survival. VitD and analogs showed also positive effects in in vitro studies, while only VitD was able to improve clinical parameters. Furthermore, a complex approach with plant-based diet, adequate levels for motor exercise, and/or eventual VitD supplementation could be a valuable strategy to challenge lymphomas.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aberrant Expression of CYP2W1 in Pediatric Soft Tissue Sarcomas: Clinical Significance and Potential as a Therapeutic Target. CYP2W1在小儿软组织肉瘤中的异常表达：临床意义及作为治疗靶点的潜力

IF 2.8 4区医学

Current oncology Pub Date : 2025-02-26 DOI: 10.3390/curroncol32030131

Dora Molina-Ortiz, Carmen Torres-Zárate, Rocío Cárdenas-Cardós, Daniel Hernández-Arrazola, Marco R Aguilar-Ortiz, José Palacios-Acosta, Jaime Shalkow-Klincovstein, Víctor Dorado-González, Rebeca Santes-Palacios, Elizabeth Hernández-Urzúa, Araceli Vences-Mejía

{"title":"Aberrant Expression of CYP2W1 in Pediatric Soft Tissue Sarcomas: Clinical Significance and Potential as a Therapeutic Target.","authors":"Dora Molina-Ortiz, Carmen Torres-Zárate, Rocío Cárdenas-Cardós, Daniel Hernández-Arrazola, Marco R Aguilar-Ortiz, José Palacios-Acosta, Jaime Shalkow-Klincovstein, Víctor Dorado-González, Rebeca Santes-Palacios, Elizabeth Hernández-Urzúa, Araceli Vences-Mejía","doi":"10.3390/curroncol32030131","DOIUrl":"10.3390/curroncol32030131","url":null,"abstract":"Pediatric soft-tissue sarcomas (STSs) are aggressive malignancies with poor prognoses, particularly in recurrent and metastatic cases. Standard therapies, such as cytotoxic chemotherapy, offer limited survival benefits and carry significant toxicities, underscoring the urgent need for innovative therapeutic approaches. CYP2W1, a tumor-specific monooxygenase enzyme, has emerged as a promising therapeutic target due to its aberrant expression in various cancers. However, its role in pediatric STSs remains poorly understood. This study evaluated CYP2W1 expression in 42 pediatric STS samples across seven histological subtypes using qPCR and Western blot analyses. High CYP2W1 expression was detected in 69% of tumor samples at the mRNA level and in 40.5% at the protein level, compared to absent or negligible expression in matched normal tissues (p < 0.001). Synovial sarcoma and rhabdomyosarcoma subtypes exhibited the highest CYP2W1 protein expression, at 70% and 62.5%, respectively. Furthermore, CYP2W1 expression was significantly associated with higher histological grade, advanced tumor stage, and a trend toward reduced overall survival (p = 0.082). These findings indicate that CYP2W1 is aberrantly expressed in a subset of pediatric STSs, contributing to tumor aggressiveness and highlighting its potential as a novel therapeutic target for these challenging malignancies.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0